Alerta

METHOD FOR OBTAINING PHOTOSENSITIVE NANOPOLYMERS TO ENCAPSULATE HYDROPHILIC AND HYDROPHOBIC MOLECULES

Resumen de: WO2026047578A1

The present invention relates to a method for synthesising a photosensitive polyethylene glycol (PEG) and methyl ether-poly(d,l-lactide) (PDLLA) polymer by tosylating its organic group. The photosensitive PEG-PDLLA polymer is functionalised by opening the Lactide monomer ring by polymerising and covalently bonding with the alcohol terminal group of PEG via an esterification with the tosylated organic group. The nanopolymer obtained using the disclosed method is suitable for controlled release processes of hydrophobic and hydrophilic active ingredients with specific delivery based on photodynamic therapy. The PEG-PDLLA-based nanopolymer obtained is able to encapsulate hydrophobic and hydrophilic active ingredients, configuring a nanocarrier with amphiphilic filler with high potential for photodynamic therapy. The method in turn involves nanoprecipitation by removing the organic solvent with optimal photo response properties to UV light.

NANOPARTICLE SYSTEM COMPRISING A METAL COATED WITH POLYETHYLENE GLYCOL (PEG) AND FUNCTIONALISED WITH A POLYPHENOL ORGANIC ACID, MANUFACTURING METHOD AND USE OF SAID SYSTEM

Resumen de: WO2026047271A1

The present invention relates to a nanoparticle system comprising a metal selected from silver and gold, coated with polyethylene glycol (PEG) and functionalised with a polyphenol organic acid selected from caffeic acid, gallic acid and ferulic acid. The present invention also relates to a method for manufacturing said nanoparticle system and to the therapeutic and cosmetic use of said nanoparticle system.

USE OF TRNA IN PROMOTING PROTEIN-CODING ABILITY OF MRNA

Resumen de: WO2026045748A1

The present invention relates to the use of tRNA in promoting the protein-coding ability of mRNA. The expression level of a target protein is improved by means of overexpressing tRNA, and a codon corresponding to the tRNA can promote or improve the stability of the mRNA. Further provided is a new tRNA+mRNA immunopotentiating vaccine. By means of introducing one or more tRNA molecules, the antigen protein encoding ability of an mRNA vaccine is enhanced, thereby eliciting stronger humoral and cellular immune responses in vivo. Further provided is a recombinant cell for producing an antibody. The recombinant cell overexpresses tRNA capable of increasing the expression level of the antibody, and the tRNA comprises a tRNA isodecoder family. Further provided is a recombinant cell for producing or packaging recombinant AAV, wherein the recombinant cell overexpresses tRNA capable of improving the AAV packaging efficiency.

POLYMERIC NANOPARTICLES FOR DIAGNOSIS AND TREATMENT OF RADIOTHERAPY-INDUCED BRAIN INJURY

Resumen de: WO2026050738A1

The present disclosure provides polymeric nanoparticles including block copolymers which possess reactive oxygen species (ROS) quenching units to reduce oxidative stress to prevent neurodegeneration and which can also be used to encapsulate an active pharmaceutical ingredient, a diagnostic marker, or a combination thereof in a pharmaceutical composition. The polymeric nanoparticles of the present disclosure are designed to release ROS quenchers, the active pharmaceutical ingredient, the diagnostic marker, or the combination thereof upon exposure to a pH below about 6.5, exposure to a reactive oxygen species, or a combination thereof. Methods of diagnosing or treating radiotherapy-induced brain injuries in a patient are also described.

COMPOSITIONS AND METHODS FOR TREATMENT OF HEPATITIS B

Resumen de: WO2026050750A1

The present invention is related to compositions and methods for modifying the hepatitis B virus (HB V) genome using CRISPR gene editing technology to treat a subject suffering from HBV. The present invention is also related to compositions of modified HB V genomes.

NUCLEAR TRANSLOCATION ENABLING SEQUENCES FOR INCREASED GENE THERAPY POTENCY

Resumen de: WO2026050148A1

Non-viral gene therapy treatments have a number of advantages over viral vectors including typical non-antigenicity, low manufacturing cost, simplicity, and efficiency of delivering genetic cargo into the cytoplasm. The potency of non-viral gene therapy systems can be enhanced by providing them with means to more efficiently transport the delivered DNA from the cytoplasm to the nucleus. Provided herein, at least in part, are means of enhancing potency of non-viral gene therapies by including novel nuclear translocation enhancing sequences and compositions that can result in optimized nuclear translocation as well as related compositions and methods.

SURFACE MODIFIED DENDRIMER FOR CONTROLLED RELEASE OF ACTIVE INGREDIENTS INTO THE SKIN

Resumen de: WO2026050140A1

A modified nanoparticle nanocarrier system for delivering one or more active ingredients into a skin that can slowly release the active ingredients is provided. The modified nanoparticle nanocarrier system comprises a dendrimer, a linker and a peptide, wherein the dendrimer is first coated with the linker to form a dendrimer-linker conjugate, and the dendrimer-linker conjugate is then coupled to a peptide to form a dendrimer-linker-peptide conjugate. Subsequently, the dendrimer-linker-peptide conjugate is loaded with one or more active ingredients and mixed with a topical base to form a homogenized product to be applied onto the skin.

SURFACTANT CONTAINING BRANCHED HYDROPHOBIC CHAINS WITH AMINO ACID RESIDUES AT THE BRANCHING POINT

Resumen de: WO2026049650A1

The invention relates to the fields of colloidal chemistry and medicinal chemistry. A surfactant containing branched hydrophobic chains with amino acid residues at the branching point is characterized by general formula (I), where R1-A-R2 represents an amino acid residue; k can be equal to 1, 2 or 3; l can be equal to 3, 4, 5, 6 or 7; the amino acid residue has an L configuration; R1 and R2 are the same or different residues from the list shown; m is an integer from 4 to 13. New compounds are obtained which provide for better binding of molecules inside lipid nanoparticles (LNPs), as well as more uniform packing of molecules inside LNPs, without the formation of ordered phases such as a lamellar phase.

COMPOSITION FOR ALLEVIATING OR TREATING HAIR LOSS HAVING HAIR LOSS DRUG LOADED IN LIPID NANOPARTICLES

Resumen de: WO2026049467A1

The present invention relates to a composition for alleviating or treating hair loss in which a hair loss drug is loaded in lipid nanoparticles. The lipid nanoparticles contain 0.30 mol% or more of a hydrophobic drug such as finasteride or dutasteride relative to the lipid nanoparticles and are loaded with the hydrophobic drug at an encapsulation rate of 90.0% or more, and thus have the advantage of being able to maintain water dispersibility for a long period of time while increasing transdermal delivery. Therefore, the present invention can more effectively alleviate symptoms of male pattern hair loss on the scalp where localized hair loss or thinning of hair occurs.

NANOPARTICLE AND PHARMACEUTICAL COMPOSITION

Resumen de: WO2026048880A1

The present invention provides a nanoparticle with which it is possible, safely, efficiently, and stably over a long period of time, to introduce siRNA used for RNA interference into an intervertebral disk cell. This nanoparticle is used for prevention or treatment of intervertebral disk degeneration, and has a biodegradable hydrogel and a ribonucleic acid molecule that is retained by a particle of the biodegradable hydrogel and that selectively inhibits an activity of a mammalian target of rapamycin (mTOR) complex.

HYDROGEL PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE FOR TREATMENT OF CANCER

Resumen de: WO2026047519A1

Described herein are pharmaceutical compositions and methods of their use for the treatment of cancer. The pharmaceutical compositions comprise a first anticancer drug formulated as nanoparticles or microparticles, the nanoparticles or microparticles uniformly dispersed in the injectable hydrogel polymer matrix formulation. This matrix comprises an anionic polymer and an inverse thermal gelling polymer, which transitions from a liquid to a gel state at specific temperatures and demonstrates shear-thinning properties to facilitate injection and gel reformation. The pharmaceutical compositions are administered intratumorally into solid tumors to treat cancer in a subject requiring such treatment. The method may additionally include systemic administration of a therapeutically effective amount of a second anticancer drug.

LUNG-TARGETING LIPID COMPOUND

Resumen de: WO2026046237A1

Provided is a lung-targeting lipid compound, specifically relating to a compound as shown in formula (I), or an isotopic variant, tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt thereof. Also provided are a nanoparticle pharmaceutical composition comprising the compound, and a use of the compound and the composition thereof in lung targeted delivery of nucleic acids.

METAL-ORGANIC FRAMEWORK NANOMATERIAL, PREPARATION THEREFOR AND USE THEREOF

Resumen de: WO2026045510A1

Provided are a metal-organic framework nanomaterial, a preparation method therefor, and a use thereof, belonging to the technical field of bionanomaterials, and resolving the technical problem of inhibiting atherosclerosis using biomimetic metal-organic framework nanoenzymes. The solution is: the components of the of the metal-organic framework nanomaterial and the ratio thereof are: metal ions Ce4+ and a ligand fumaric acid in a molar ratio of 1:5. The preparation method therefor is: measuring an FA regulator and water to prepare a mixed solution, then adding fumaric acid and cerium ammonium nitrate dropwise into the mixed solution, stirring at room temperature, centrifuging, repeatedly washing alternately with water and ethanol, and finally drying overnight in a vacuum oven. A simple, efficient and convenient method for synthesizing the metal-organic framework nanomaterial is provided. The synthesized metal-organic framework nanomaterial has excellent CEH-like enzyme activity and intrinsic antioxidant activity, and can be used to increase lipid efflux and reduce lipid uptake, and decrease ox-LDL-induced foam cell formation, thereby alleviating atherosclerosis.

LIPID NANOPARTICLE (LNP) COMPOSITION OR FORMULATION FOR NUCLEIC ACID THERAPEUTICS

Resumen de: US20260062716A1

The present disclosure relates generally to lipid nanoparticle compositions comprising a nucleic acid, an ionizable polymer, a cationic lipid, a phospholipid, a sterol, and a PEG-lipid. Further, the present disclosure relates generally to methods of treating or preventing a disease, comprising administering to a subject in need thereof a lipid nanoparticle composition described herein.

MODIFIED MESSENGER RNA COMPRISING FUNCTIONAL RNA ELEMENTS

Resumen de: US20260062697A1

The present disclosure provides messenger RNAs (mRNAs) having chemical and/or structural modifications, including RNA elements and/or modified nucleotides, which provide a desired translational regulatory activity to the mRNA.

免疫療法構築物およびその使用方法

Resumen de: US2025195641A1

Disclosed herein are immunotherapeutic constructs comprising a delivery particle, at least one adjuvant, and one or more therapeutic agents/compounds that cause antigen release and/or modulate immunosuppressive tumor microenvironment. These immunotherapeutic constructs create adaptive immunity or anti-cancer immune response(s) that can be used, for instance, to prevent and treat broad types of cancer. Further disclosed are uses of the immunotherapeutic constructs, including to prevent and treat cancer in humans and animals.

抗イヌＣＤ２０抗体

Resumen de: US2025297026A1

The invention relates to antibodies and antigen binding portions thereof that binds canine CD20. The present invention also relates to compositions and methods for the treatment of a condition mediated by B-cells in a canine subject.

NEW CLOFOCTOL FORMULATION

Resumen de: WO2024223624A1

The invention concerns a new galenic formulation of CFT (clofoctol) allowing the administration of this antibiotic in aerosol form with the objective of treating pulmonary infections (COVID-19, influenza), cancer and inflammation thus targeting the diseased tissue while avoiding the problems of solubility of CFT and toxicity associated with this drug. This new formulation allows to answer these problems and concerns the development of polymeric nanoparticles (Nanoparticles) in suspension in an aqueous phase intended to be administrated in a form of aerosol or spray, said Nanoparticles comprising PLGA and PLGA-PEG polymers, allowing to obtain an effective encapsulation of CFT and a controlled release of CFT at the pulmonary level.

PROGRAMMABLE NUCLEASE RESISTANCE OF NUCLEIC ACID ASSEMBLIES

Resumen de: US20260053933A1

The present invention provides nuclease-resistant nucleic acid nanostructures, pharmaceutical compositions thereof, pharmaceutical and diagnostic uses thereof as well as a method of producing nucleic acid nanostructures.

グリコーゲンシンターゼキナーゼ－３の活性調節のための、グルタチオンコーティング及びリチウム官能化金ナノ粒子（ＬｉＧ－ＡｕＮＰ）の使用

Resumen de: WO2024165949A1

The present invention relates to a method for the production of gold nanoparticles (AuNPs) coated with glutathione and Li+ ions, hereinafter designated as LiG-AuNPs, to a method for the preparation of aggregates of said nanoparticles and to the use of said nanoparticles, aggregates or compositions thereof which comprise them for therapeutic use. LiG-AuNPs then are an effective instrument in inhibiting GSK-3 and its downstream molecular targets, while keeping the lithium extracellular concentration levels below the systemic toxicity threshold (1.5 mEq/L), and exerting an antioxidant action by means of the glutathione present on their surface.

NEW EPITHELIAL PERMEATION ENHANCER

Resumen de: WO2024245589A1

The invention relates to a composition comprising a cold-water insoluble crosslinked dextrin and a fatty acid having 8 to 17 carbon atoms. This invention also relates to a method for making such composition. The invention also relates to the use of a combination of a cold-water insoluble crosslinked dextrin and of a fatty acid having 8 to 17 carbon atoms for increasing the epithelial permeation of an active ingredient, or for the epithelial delivery of an active ingredient.

N-CADHERIN TARGETING CHIMERIC PEPTIDES FOR INHIBITING RESTENOSIS

Resumen de: CA3205091A1

Novel chimeric peptides comprise an N-cadherin binding domain for binding N-cadherin, which is expressed on the surface of cells, in particular smooth muscle cells, and a fibronectin-binding domain, which binds surrounding extracellular matrix and a binding site for fibronectin. The chimeric peptides can be loaded on to nanoparticles, suitably degradable polar hydrophobic ionic polyurethane (D-PHI) nanoparticles for delivery, which can be incorporated into coatings for medical devices, including stents and balloons.

In vivo nickase-based editing of the LPA gene for treatment of cardiovascular disease

Resumen de: GB2643844A

Provided herein are gene editing systems and compositions directed to effectuate in vivo edits in the LPA gene. Treatment or prevention of cardiovascular disease through disruption of the production of apo(a) through genetic editing and the reduction of the blood lipoprotein(a) Lp(a) concentration is disclosed herein. Disclosed are nickase-based gene editing systems designed to effectuate the installation of insertions and/or deletions (indel variants) and/or non-synonymous variants in the coding sequence of LPA. The nickase-based gene editing systems generally comprise one or more mRNAs that encode one or more nickases and a plurality of guide oligonucleotides (e.g., gRNAs) and may be delivered in vivo to a mammalian subject in need thereof via a suitable delivery system, such as lipid nanoparticles (LNPs) (with or without GalNAc targeting moieties) intravenously, or otherwise, administered to a patient as potentially a once-and-done therapeutic. The manufacturing, use, and formulation of the gene editing systems and compositions are also disclosed.

METHOD FOR THE PRODUCTION OF PLANT-DERIVED NANOVESICLES AND THEIR APPLICATIONS

Resumen de: US20260048012A1

The present invention concerns a method for the production, purification, and stabilization of plant-derived nanovesicles (PDVs). It also concerns a pharmaceutical composition comprising the PDVs obtained by this method for hypocholesterolemic, hypoglycemic, hypolipidemic, anti-ageing, and antioxidant use.

一种手性可电离脂质纳米颗粒及其制备方法

Nº publicación: CN121588063A 03/03/2026

Solicitante:

北京科技大学

Resumen de: CN121588063A

一种手性可电离脂质纳米颗粒及其制备方法，属于生物医用材料技术领域。手性可电离脂质纳米颗粒包含：手性氨基酸衍生脂质、可电离脂质、辅助脂质、胆固醇、磷脂聚乙二醇衍生物及RNA药物；将手性氨基酸衍生脂质溶解于甲醇中，可电离脂质、辅助脂质、胆固醇和磷脂聚乙二醇衍生物分别溶解在乙醇中混合，得到总脂质有机相；再将RNA药物溶解在DEPC水中，得到RNA水溶液后和酸性缓冲液混合，得到RNA水相；将总脂质有机相和RNA水相快速混合后静置孵育；将混合液加入3500 Da透析袋，以1×磷酸盐缓冲液（PBS，pH=7.4）为外水相，透析后得手性可电离脂质纳米颗粒。本发明的脂质纳米颗粒能够增强RNA摄取效率，在系统性炎症等疾病治疗方面具有很好的应用前景。